EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma

Omar Elghawy iD, Saarang Deshpande iD, Jonathan Sussman iD, Alfred Garfall, Adam Cohen iD, Shivani Kapur, Sandra Susanibar-Adaniya, Dan Vogl iD, Adam Waxman, Edward Stadtmauer

Bone Marrow Transplantation · 2025

DOI: 10.1038/s41409-024-02455-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bone Marrow Transplantation, 2025. Verfasst von Omar Elghawy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation, Transplantation, Autologous, Neoplasms, Second Primary. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With a prolonging duration of survivorship, patients with multiple myeloma (MM) who receive high-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-HCT) have an increased risk of secondary malignancy, most concerning acute leukemia. We retrospectively reviewed the records of all patients with MM who underwent auto-HCT between January 1, 2010, and January 1, 2023, who later developed therapy-related acute leukemia (t-AL). Of 1770 patients with MM who underwent auto-HCT, 18 (1.01%) developed t-AL at a mean interval of 60.0 ± 41.3 months after auto-HCT. The patients with t-AL consisted of 9 (50%) with B-cell acute lymphoblastic leukemia (B-ALL), 8 (44.4%) with acute myeloid leukemia (AML), and 1 (5.6%) with acute promyelocytic leukemia (APML). All patients had received an alkylating agent as part of induction, and the majority received lenalidomide as maintenance therapy. Genetic abnormalities of t-AL were consistent with prior reports. Median overall survival from diagnosis of t-AL was 19.5 months. In patients with t-AL who entered CR, long term survival was common. Further research on predisposing conditions to developing t-AL in patients with MM undergoing auto-HCT is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHematopoietic Stem Cell TransplantationTransplantation, AutologousNeoplasms, Second PrimaryLeukemia, Myeloid, AcuteHumansMaleFemaleMiddle AgedRetrospective StudiesAdultAged

Autor:innen und Institutionen

  • Division of Hematology Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
  • Division of Hematology Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Edward.stadtmauer@pennmedicine.upenn.edu.
  • Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. Edward.stadtmauer@pennmedicine.upenn.edu.

ORCID-Profile: Omar Elghawy, Saarang Deshpande, Jonathan Sussman, Adam Cohen, Dan Vogl

Zitieren

APA

Elghawy, O., Deshpande, S., Sussman, J., Garfall, A., Cohen, A., Kapur, S., Susanibar-Adaniya, S., Vogl, D., Waxman, A., & Stadtmauer, E. (2025). Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-024-02455-4

Vancouver

Elghawy O, Deshpande S, Sussman J, Garfall A, Cohen A, Kapur S, et al. Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma. Bone Marrow Transplantation. 2025. doi:10.1038/s41409-024-02455-4

BibTeX
@article{Elghawy2025,
  author = {Elghawy, Omar and Deshpande, Saarang and Sussman, Jonathan and Garfall, Alfred and Cohen, Adam and Kapur, Shivani and Susanibar-Adaniya, Sandra and Vogl, Dan and Waxman, Adam and Stadtmauer, Edward},
  title = {Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma},
  journal = {Bone Marrow Transplantation},
  year = {2025},
  doi = {10.1038/s41409-024-02455-4}
}
Kostenlos starten →